Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
ACC 2023 program chair Douglas Drachman, MD, explains the top takeaways from the American College of Cardiology meeting. #ACC #ACC23

Key takeaways from the ACC 2023 annual meeting

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

Thumbnail

What new data tell us about TAVR in women with a history of early menopause

Researchers examined data from more than 700 TAVR patients, publishing their findings in the American Journal of Cardiology.

B. Hadley Wilson, ACC President ACC.23

New American College of Cardiology President B. Hadley Wilson shares his goals for the future

The veteran interventional cardiologist told Cardiovascular Business he sees potential in the ACC's ability to grow both nationally and internationally in the next year. 

ACC 2023 ACC.23 American College of Cardiology

Day 2 at ACC.23 features late-breaking studies on TEER, TAVR, EHR alerts and much more

Catch up on the biggest news that came out of the second day of ACC.23 in New Orleans. 

ACC.23 Together with the World Congress of Cardiology

Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair and statins

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

10 reasons heart teams may consider SAVR over TAVR when treating aortic stenosis

As much as TAVR's popularity has grown in recent years, there are still many instances when a heart team may find that surgery offers the best path forward. 

Medtronic, Abbott share late-breaking TAVR data at CRT 2023

Both vendors used the four-day conference as an opportunity to provide key updates about their TAVR valves.

Abbott and the U.S. Food and Drug Administration (FDA) are warning healthcare providers about the potential risk of early structural valve deterioration (SVD) with Abbott’s line of Trifecta bioprosthetic heart valves. This includes the original Trifecta valve and the Trifecta GT, which are both designed to treat disease, damaged or malfunctioning aortic heart valves.

FDA warns that early deterioration is possible with Abbott’s Trifecta heart valves

Early SVD has been reported in these devices, particularly three to four years after implantation. According to the FDA, this has resulted in surgical replacement procedures and transcatheter valve-in-valve interventions. In some cases, the patient died.

Displaying 305 - 312 of 2332

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.